Trial Information

Summary: ITN020AI: A Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patient with Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (MS) (STAYCIS)

The main goal of this study is to evaluate the effects of atorvastatin, an experimental drug, on lessening or slowing down the advancement of Multiple Sclerosis as seen by MRI and clinical symptoms in patients with clinically isolated syndrome (CIS)
Compensation Provided

Patient Inclusion/Exclusion Criteria:

1. Male and non-pregnant females.
2. 18-55 years of age
3. Patients who present with clinically isolated syndrome (CIS, which means having neurological symptoms, lasting at least 48 hours, that relate to MS.
4. No history of neurological symptoms lasting more than 48 hours.

1. Patients that have a definite diagnosis of Multiple Sclerosis.
2. Prior use of interferon, glatiramer acetate (Copaxone), cyclophosphamide, mitoxantrone, or plasmapheresis at any time.
3. Use of interferon, glatiramer acetate (Copaxone), cyclophosphamide, mitoxantrone, or plasmapheresis during the trial.
4. History of substance abuse 12 months before the start of the trial.
5. Metallic objects on or inside the body.
6. Need to use a medication to lower cholesterol during three months before the first visit or during the study.
7. Major medical illness or psychiatric impairment that will prevent completion of the study.
8. Pregnant or breastfeeding women.
9. Participants who have received more that 5 mg or methylprednisone (or equivalent of other corticosteroid) before screening.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.